Item 2.01. Completion of Acquisition or Disposition of Assets
On November 15, 2018, the Company completed its previously announced acquisition of Genewiz, a leading global genomics service provider headquartered in South Plainfield, New Jersey. Pursuant to the Agreement of Merger, dated as of September 26, 2018 (the Merger Agreement), by and among the Company, Darwin Acquisition Company, an exempted company with limited liability incorporated under the Laws of the Cayman Islands and wholly owned subsidiary of the Company, Genewiz and Shareholder Representative Services LLC, as the representative of the securityholders of Genewiz, the Company paid a total cash purchase price at closing of $450.0 million, which is subject to adjustment based on Genewizs cash, transaction expenses, net working capital, indebtedness, accounts receivables (subject to a collar) and other amounts as of the closing. The Company used the proceeds of the Incremental Loan described in Item 1.01 to pay a portion of the purchase price.
On November 15, 2018, the Company completed its previously announced acquisition of Genewiz, a leading global genomics service provider headquartered in South Plainfield, New Jersey. Pursuant to the Agreement of Merger, dated as of September 26, 2018 (the Merger Agreement), by and among the Company, Darwin Acquisition Company, an exempted company with limited liability incorporated under the Laws of the Cayman Islands and wholly owned subsidiary of the Company, Genewiz and Shareholder Representative Services LLC, as the representative of the securityholders of Genewiz, the Company paid a total cash purchase price at closing of $450.0 million, which is subject to adjustment based on Genewizs cash, transaction expenses, net working capital, indebtedness, accounts receivables (subject to a collar) and other amounts as of the closing. The Company used the proceeds of the Incremental Loan described in Item 1.01 to pay a portion of the purchase price.
The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
